Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic Cancer
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This phase-2 monocenter non-randomized prospective clinical trial evaluates the effectiveness
of minimally invasive microwave ablation plus immunotherapy for unresectable non-metastatic
locally advanced pancreatic cancer.